Acute Promyelocytic Leukemia News and Research

RSS

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) and is characterized by a unique molecular abnormality. This type of leukemia has a high mortality rate and is associated with early hemorrhagic death.

Case report and review of a novel chromosomal abnormality in AML patient

A new research paper was published in Genes & Cancer on June 28, 2023, entitled, "A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature."

7 Jul 2023

UCSD engineers develop a biodegradable polymer system to treat rheumatoid arthritis

A team led by engineers at the University of California San Diego has developed a biodegradable polymer system to treat rheumatoid arthritis, an autoimmune and inflammatory disease, by working in concert with the power of the human immune system.

4 Apr 2023

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

The use of a simplified treatment regimen by oncologists, along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts, resulted in a dramatic decrease in early deaths from acute promyelocytic leukemia (APL).

12 Dec 2022

New research finds disturbing lack of crucial blood cancer medication

New research in the November 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA).

16 Nov 2021

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.

11 Nov 2021

Pinning down Pin1: Potential COVID-19 therapy

In a recent study scientists have demonstrated that Pin1 is one of the key cellular molecules necessary for SARS-CoV-2 propagation.

22 Sep 2021

Adolescent and young adult cancer patients found to be well represented in NCI-sponsored clinical trials

Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival over the years as their pediatric and older adult counterparts.

10 Aug 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

A review of the literature on acute promyelocytic leukemia

Oncotarget Volume 11, Issue 11 reported that relapsed APL, particularly in the high-risk subset of patients, remains an important clinical problem.

22 Mar 2020

Leukemia is not just one disease

An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year, with some 2,000 cases in New Jersey, according to the American Cancer Society.

30 Aug 2019

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Combination of arsenic and existing leukemia drug may combat cancer

Investigators have discovered that arsenic in combination with an existing leukemia drug work together to target a master cancer regulator.

9 Aug 2018

Arsenic trioxide could be powerful therapy to extend lives of certain glioblastoma patients

From Sherlock Holmes to Agatha Christie, arsenic is often the poison of choice in popular whodunits. But in ultra-low dosage, and in the right form, this naturally occurring chemical element can be a potent force against cancer.

17 Oct 2017

Scientists identify new genetic variations contributing to onset of APL

A study led by a team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore has identified new genetic alterations contributing to the onset of Acute Promyelocytic Leukemia (APL).

27 Jul 2016

Arsenic induces acute promyelocytic leukemia remission

Elderly patients with acute promyelocytic leukemia have a high rate of response to arsenic trioxide, say researchers who believe the drug should be a first-line treatment in this population.

5 Sep 2012

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Acute Promyelocytic Leukemia News and Research

Further Reading